Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: The long-term outcome of never-treated patients with schizophrenia is unclear. Aims: To compare the 14-year outcomes of never-treated and treated patients with schizophrenia and to establish predictors for never being treated. Method: All participants with schizophrenia (n= 510) in Xinjin, Chengdu, China were identified in an epidemiological investigation of 123 572 people and followed up from 1994 to 2008. Results: The results showed that there were 30.6%, 25.0% and 20.4% of patients who received no antipsychotic medication in 1994, 2004 and 2008 respectively. Compared with treated patients, those who were never treated in 2008 were significantly older, had significantly fewer family members, had higher rates of homelessness, death from other causes, being unmarried, living alone, being without a caregiver and poor family attitudes. Partial and complete remission in treated patients (57.3%) was significantly higher than that in the never-treated group (29.8%). Predictors of being in the never-treated group in 2008 encompassed baseline never-treated status, being without a caregiver and poor mental health status in 1994. Conclusions: Many patients with schizophrenia still do not receive antipsychotic medication in rural areas of China. The 14-year follow-up showed that outcomes for the untreated group were worse. Community-based mental healthcare, health insurance and family intervention are crucial for earlier diagnosis, treatment and rehabilitation in the community.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., Day, R., & Bertelsen, A. (1992) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000904 · Cited by 1,769
Mueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Neuroleptics and the Natural Course of Schizophrenia
Wyatt, R. J. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.325 · Cited by 787
Sartorius, N., Gulbinat, W., Harrison, G., Laska, E., & Siegel, C. (1996) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00787917 · Cited by 208
Cited by
Patel, V., Xiao, S., Chen, H., Hanna, F., Jotheeswaran, A. T., Luo, D., Parikh, R., Sharma, E., Usmani, S., Yu, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00160-4 · Cited by 342
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Vermeulen, J., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M., & de Haan, L. (2017) · Psychological Medicine · doi:10.1017/s0033291717000873 · Cited by 134
“3, 2,127/1,198, specified in strata (Ran et al., 2015)”
CMHP Study Group, Zhang, T.-M., Wong, I. Y.-L., Yu, Y.-H., Ni, S.-G., He, X.-S., Bacon-Shone, J., Gong, K., Huang, C.-H., Hu, Y., et al. (2019) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-018-1646-3 · Cited by 56
Self-citationTaylor, M., & Jauhar, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319870033 · Cited by 51
Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937910 · Cited by 43
Huhn, M., Leucht, C., Rothe, P., Dold, M., Heres, S., Bornschein, S., Schneider-Axmann, T., Hasan, A., & Leucht, S. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01109-y · Cited by 38
Metadata
- Authors
- Ran, M.-S., Weng, X., Chan, C. L.-W., Chen, E. Y.-H., Tang, C.-P., Lin, F.-R., Mao, W.-J., Hu, S.-H., Huang, Y.-Q., & Xiang, M.-Z.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2015-12
- Volume
- 207
- Issue
- 6
- Pages
- 495-500
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2183549014
- Cited by
- 86
- References
- 5
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.